What is the appropriate evaluation and treatment for a patient with meal‑related epigastric pain and early satiety, without nausea, vomiting, melena, or fever?

Evaluation and Management of Meal-Related Epigastric Pain with Early Satiety

This presentation is consistent with functional dyspepsia, specifically postprandial distress syndrome (PDS), and you should initiate a "test and treat" strategy for H. pylori in patients under age 55 without alarm features, followed by empirical therapy if symptoms persist. 1

Initial Diagnostic Approach

The symptom pattern—meal-related pain with early satiety, absent nausea, vomiting, melena, or fever—strongly suggests functional dyspepsia rather than organic pathology. The British Society of Gastroenterology 2022 guidelines provide clear age-based algorithms for evaluation 1:

For Patients Under Age 55 Without Alarm Features:

• Skip endoscopy initially and proceed directly to H. pylori testing (stool antigen or urea breath test) 1
• If H. pylori positive: provide eradication therapy (this is therapeutic for functional dyspepsia, not just peptic ulcer disease) 1
• If H. pylori negative or symptoms persist after eradication: trial empirical acid suppression with PPI for 4-8 weeks 1, 2

For Patients Age 55 or Older:

• Perform endoscopy to exclude gastric cancer and other structural lesions, even without alarm features 1, 2
• Test for H. pylori during endoscopy via biopsy
• For patients age 60+ with abdominal pain and weight loss specifically, consider urgent CT abdomen to exclude pancreatic cancer 1

Additional Baseline Testing:

• Full blood count in patients ≥55 years 1
• Celiac serology only if overlapping IBS-type symptoms are present 1
• Do not routinely order gastric emptying studies, 24-hour pH monitoring, or abdominal ultrasound 1

Treatment Algorithm

First-Line Therapy:

The 2022 BSG guidelines emphasize symptom-pattern-directed treatment 1:

1. For PDS (your patient's presentation with meal-related symptoms and early satiety):

   • Consider prokinetic agents as first-line, though evidence is limited and availability varies by country 1, 3
   • Alternatively, trial PPI therapy for 4-8 weeks 1
   • Recommend regular aerobic exercise (strong recommendation despite low-quality evidence) 1

2. Avoid restrictive diets: There is insufficient evidence for FODMAP or other specialized diets, and excessive restriction risks malnutrition 1

Second-Line Therapy (If First-Line Fails):

• Tricyclic antidepressants (low-dose, e.g., amitriptyline 10-25 mg) are the most evidence-based neuromodulators 1, 3
• Mirtazapine is an alternative, particularly if weight loss is present 4
• Do not use SSRIs—they lack efficacy in functional dyspepsia 3, 5
• Consider cognitive-behavioral therapy if available 1

Critical Pitfalls to Avoid

1. Don't assume normal endoscopy means "nothing is wrong": Functional dyspepsia represents disordered gut-brain communication, not absence of pathology. Duodenal eosinophilia is increasingly recognized 6, 3

2. Don't over-investigate: Gastric emptying testing does not change management in typical functional dyspepsia and should not be routine 1, 5

3. Don't dismiss H. pylori testing: Even in functional dyspepsia (normal endoscopy), H. pylori eradication is therapeutic in infected patients 1

4. Age thresholds matter: The cutoff of 55 years for endoscopy is evidence-based on gastric cancer risk and should be respected 1, 2

When to Refer to Gastroenterology

Referral is appropriate when 1:

• Diagnostic uncertainty exists
• Symptoms are severe or refractory to first-line treatments
• Patient requests specialist opinion
• Ideally, refer to a dedicated functional GI clinic with access to dietetic support and gut-brain behavioral therapies

Establish an empathic doctor-patient relationship early: Explain that functional dyspepsia is a disorder of gut-brain interaction, not "all in their head," and that normal tests don't negate their symptoms. This approach alone may reduce healthcare utilization and improve quality of life 1.